200,000+ products from a single source!

sales@angenechem.com

Home > Other Building Blocks > 131740-09-5

131740-09-5

131740-09-5 | Flavopiridol Hydrochloride

CAS No: 131740-09-5 Catalog No: AG00385D MDL No:MFCD16876048

Product Description

Catalog Number:
AG00385D
Chemical Name:
Flavopiridol Hydrochloride
CAS Number:
131740-09-5
Molecular Formula:
C21H21Cl2NO5
Molecular Weight:
438.3011
MDL Number:
MFCD16876048
IUPAC Name:
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one;hydrochloride
InChI:
InChI=1S/C21H20ClNO5.ClH/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22;/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3;1H/t12-,17+;/m0./s1
InChI Key:
LGMSNQNWOCSPIK-LWHGMNCYSA-N
SMILES:
CN1CC[C@@H]([C@@H](C1)O)c1c(O)cc(c2c1oc(cc2=O)c1ccccc1Cl)O.Cl
UNII:
D48MS3A6N9

Properties

Complexity:
628  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
2  
Defined Bond Stereocenter Count:
0
Exact Mass:
437.08g/mol
Formal Charge:
0
Heavy Atom Count:
29  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
4  
Isotope Atom Count:
0
Molecular Weight:
438.301g/mol
Monoisotopic Mass:
437.08g/mol
Rotatable Bond Count:
2  
Topological Polar Surface Area:
90.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0

Literature

Title Journal
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells. BMC pharmacology & toxicology 20130101
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica 20121101
A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecologic oncology 20121001
CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer research 20120815
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood 20120809
Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia 20120601
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer chemotherapy and pharmacology 20120601
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research 20120501
Delayed cell cycle pathway modulation facilitates recovery after spinal cord injury. Cell cycle (Georgetown, Tex.) 20120501
A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Investigational new drugs 20120401
Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development. Cell cycle (Georgetown, Tex.) 20120315
CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. International journal of cancer 20120301
Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia. Leukemia & lymphoma 20120301
Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica 20120301
A mathematical model of cell cycle effects in gastric cancer chemotherapy. Bulletin of mathematical biology 20120101
GSK3β inhibition is involved in the neuroprotective effects of cyclin-dependent kinase inhibitors in neurons. Pharmacological research 20120101
Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis. PloS one 20120101
Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death. PloS one 20120101
Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS. NMR in biomedicine 20111101
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Investigational new drugs 20111001
Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leukemia & lymphoma 20111001
The BH3-only protein Noxa is stimulated during apoptosis of chronic lymphocytic leukemia cells triggered by M2YN, a new plant-derived extract. International journal of oncology 20111001
Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies. Expert review of hematology 20111001
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia 20110901
Acute myeloid leukaemia: optimal management and recent developments. Drugs 20110820
Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis. Cancer biology & therapy 20110815
[Present status and perspective of targeted therapy for B-cell lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology 20110801
Novel purine-based fluoroaryl-1,2,3-triazoles as neuroprotecting agents: synthesis, neuronal cell culture investigations, and CDK5 docking studies. Bioorganic & medicinal chemistry letters 20110701
Leukemia cutis in association With Grover's disease. The American Journal of dermatopathology 20110601
Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-β-mediated growth inhibition. Pigment cell & melanoma research 20110601
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clinical cancer research : an official journal of the American Association for Cancer Research 20110515
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 20110324
Flavopiridol inhibits lipopolysaccharide-induced TNF-α production through inactivation of nuclear factor-κB and mitogen-activated protein kinases in the MyD88-dependent pathway. Microbiology and immunology 20110301
Homology modeling, molecular dynamic simulation and docking studies of cyclin dependent kinase 1. Journal of molecular modeling 20110201
Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9. Arteriosclerosis, thrombosis, and vascular biology 20110201
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood 20110113
Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia 20110101
The CDK9/cyclin T1 subunits of P-TEFb in mouse oocytes and preimplantation embryos: a possible role in embryonic genome activation. BMC developmental biology 20110101
CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Molecular endocrinology (Baltimore, Md.) 20101201
Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia. Proteomics 20101201
Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. Molecular cancer therapeutics 20101201
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer biology & therapy 20101101
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer chemotherapy and pharmacology 20101101
Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini reviews in medicinal chemistry 20101001
[Synergism of antitumor effects on ovarian carcinoma using autocatalytic caspase-3 combined with flavopiridol]. Zhonghua fu chan ke za zhi 20101001
P-TEFb kinase complex phosphorylates histone H1 to regulate expression of cellular and HIV-1 genes. The Journal of biological chemistry 20100924
Live-cell imaging RNAi screen identifies PP2A-B55alpha and importin-beta1 as key mitotic exit regulators in human cells. Nature cell biology 20100901
A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer. American journal of clinical oncology 20100801
Human chorionic gonadotropin up-regulates expression of myeloid cell leukemia-1 protein in human granulosa-lutein cells: implication of corpus luteum rescue and ovarian hyperstimulation syndrome. The Journal of clinical endocrinology and metabolism 20100801
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Molecular cancer therapeutics 20100801
Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents. Cancer chemotherapy and pharmacology 20100701
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leukemia research 20100701
T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes. Journal of cellular physiology 20100701
Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment. Biochemical pharmacology 20100701
Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next? Leukemia research 20100701
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica 20100701
Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. The Journal of pharmacology and experimental therapeutics 20100601
Recombinant Leishmania mexicana CRK3:CYCA has protein kinase activity in the absence of phosphorylation on the T-loop residue Thr178. Molecular and biochemical parasitology 20100601
Specificity in the interaction of natural products with their target proteins--a biochemical and structural insight. Mini reviews in medicinal chemistry 20100601
A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model. The British journal of radiology 20100501
Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. The Journal of biological chemistry 20100416
Dysoxylum binectariferum Hook.f (Meliaceae), a rich source of rohitukine. Fitoterapia 20100301
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100120
New agents in chronic lymphocytic leukemia. Current hematologic malignancy reports 20100101
The binding of flavopiridol to blood serum albumin. Chirality 20100101
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PloS one 20100101
Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen. BMC cancer 20100101
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091210
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 20091201
Misguided transcriptional elongation causes mixed lineage leukemia. PLoS biology 20091101
Flavopiridol reduces the impedance of neural prostheses in vivo without affecting recording quality. Journal of neuroscience methods 20091015
SKIP interacts with c-Myc and Menin to promote HIV-1 Tat transactivation. Molecular cell 20091009
Emerging therapies for patients with advanced chronic lymphocytic leukaemia. Blood reviews 20090901
New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines. Current oncology reports 20090901
Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. Chembiochem : a European journal of chemical biology 20090817
CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3'-end processing. EMBO reports 20090801
The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity. Haematologica 20090701
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 20090507
The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug metabolism and disposition: the biological fate of chemicals 20090501
Camptothecin releases P-TEFb from the inactive 7SK snRNP complex. Cell cycle (Georgetown, Tex.) 20090415
Transforming growth factor-{beta}-inducible phosphorylation of Smad3. The Journal of biological chemistry 20090410
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 20090319
Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer chemotherapy and pharmacology 20090301
Noxa upregulation is associated with apoptosis of chronic lymphocytic leukemia cells induced by hyperforin but not flavopiridol. Leukemia 20090301
Role of the HIV-1 positive elongation factor P-TEFb and inhibitors thereof. Mini reviews in medicinal chemistry 20090301
Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 20090215
A novel liposomal formulation of flavopiridol. International journal of pharmaceutics 20090105
Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. The International journal of biological markers 20090101
A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20090101
Flavopiridol in chronic lymphocytic leukemia: a concise review. Clinical lymphoma & myeloma 20090101
Future research directions for the treatment of AML. Clinical advances in hematology & oncology : H&O 20081101
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. Therapeutic drug monitoring 20081001
Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol. Molecular pharmacology 20080901
Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed. International journal of radiation oncology, biology, physics 20080801
Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies. Clinical lymphoma & myeloma 20080801
The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. The EMBO journal 20080709
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080601
Flavopiridol-induced iNOS downregulation during apoptosis of chronic lymphocytic leukemia cells is caspase-dependent. Leukemia research 20080501
Delayed combinatorial treatment with flavopiridol and minocycline provides longer term protection for neuronal soma but not dendrites following global ischemia. Journal of neurochemistry 20080501
Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells. Molecular pharmacology 20080501
Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer. Clinical lung cancer 20080501
Flavopiridol displays preclinical activity in acute lymphoblastic leukemia. Pediatric blood & cancer 20080401
The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer research 20080401
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 20080315
P-TEFb inhibitors interfere with activation of p53 by DNA-damaging agents. Oncogene 20080221
Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors. Journal of immunology (Baltimore, Md. : 1950) 20080201
Transcription-dependent gene looping of the HIV-1 provirus is dictated by recognition of pre-mRNA processing signals. Molecular cell 20080118
Rhabdoid tumor growth is inhibited by flavopiridol. Clinical cancer research : an official journal of the American Association for Cancer Research 20080115
The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression. The Journal of biological chemistry 20071221
Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Drug metabolism and disposition: the biological fate of chemicals 20071201
Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Molecular cancer therapeutics 20071201
Cell cycle activation contributes to post-mitotic cell death and secondary damage after spinal cord injury. Brain : a journal of neurology 20071101
Flavopiridol in the treatment of chronic lymphocytic leukemia. Current opinion in oncology 20071101
[Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma]. Zhonghua fu chan ke za zhi 20071101
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 20071001
Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells. International journal of cancer 20070915
Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best practice & research. Clinical haematology 20070901
Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL. Cancer chemotherapy and pharmacology 20070801
UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenetics and genomics 20070801
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 20070801
[DMF induces apoptosis in human androgen-independent prostate cancer PC3 cells in vitro]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20070501
[Research on cyclin-dependent kinase inhibitors: state of the art and perspective]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070501
In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia. British journal of haematology 20070401
Levels of p27(kip1) determine Aplidin sensitivity. Molecular cancer therapeutics 20070401
Small molecule inhibitors of Stat3 signaling pathway. Current cancer drug targets 20070201
Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. Molecular cancer therapeutics 20070201
Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia. Hematology (Amsterdam, Netherlands) 20070201
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 20070115
Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues. Bioorganic & medicinal chemistry 20070115
Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology 20070101
Bioactivity of glycogen phosphorylase inhibitors that bind to the purine nucleoside site. Bioorganic & medicinal chemistry 20061201
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer research 20061201
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer research 20061115
Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment. Leukemia research 20061101
Antisense inhibition of cyclin D1 expression is equivalent to flavopiridol for radiosensitization of zebrafish embryos. International journal of radiation oncology, biology, physics 20061001
Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Ggamma/T-15 transgenic mouse model of prostate cancer. The Prostate 20061001
Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil. Acta pharmacologica Sinica 20061001
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer research 20060915
Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection. Cell death and differentiation 20060901
Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer research 20060901
The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis. International journal of molecular medicine 20060801
Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20060801
Alvocidib (Flavopiridol) suppresses tumor growth in SCID mice with human esophageal cancer xenografts without inducing apoptosis. Surgical oncology 20060801
MicroRNAs in leukemia. Clinical advances in hematology & oncology : H&O 20060801
A phase I study of flavopiridol and docetaxel. Investigational new drugs 20060701
Cyclin dependent kinase inhibitors prevent apoptosis of postmitotic mouse motoneurons. Life sciences 20060627
Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer research 20060601
Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells. Molecular cancer therapeutics 20060501
The reversibility of mitotic exit in vertebrate cells. Nature 20060413
The first metal-based paullone derivative with high antiproliferative activity in vitro. Inorganic chemistry 20060306
Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica 20060301
Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2. Molecular pharmacology 20060101
Radiation sensitivity of GL261 murine glioma model and enhanced radiation response by flavopiridol. Cell cycle (Georgetown, Tex.) 20060101
Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein. Expert opinion on investigational drugs 20060101
Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. Molecular cancer therapeutics 20060101
A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets. Journal of natural products 20060101
Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis. Anticancer research 20060101
Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Current pharmaceutical design 20060101
Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051220
Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS (London, England) 20051202
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clinical cancer research : an official journal of the American Association for Cancer Research 20051201
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leukemia research 20051101
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 20051001
Role of the cell cycle in the pathobiology of central nervous system trauma. Cell cycle (Georgetown, Tex.) 20050901
Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clinical cancer research : an official journal of the American Association for Cancer Research 20050815
A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology 20050801
A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines. Investigational new drugs 20050801
A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia. Cancer research 20050715
Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion. Oncogene 20050714
A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109. Cancer chemotherapy and pharmacology 20050701
Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro-oncology 20050701
Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Investigational new drugs 20050601
Chronic lymphocytic leukemia: a niche for flavopiridol? Clinical cancer research : an official journal of the American Association for Cancer Research 20050601
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clinical cancer research : an official journal of the American Association for Cancer Research 20050601
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clinical cancer research : an official journal of the American Association for Cancer Research 20050515
Drugging cell cycle kinases in cancer therapy. Current drug targets 20050501
Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids. Clinical cancer research : an official journal of the American Association for Cancer Research 20050501
Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer research 20050501
Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin. Cancer biology & therapy 20050401
Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert opinion on investigational drugs 20050401
[A novel small molecule cyclin-dependent kinase inhibitor flavopiridol in cancer therapy]. Zhonghua yi xue za zhi 20050330
Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice. Oncogene 20050303
Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 20050301
Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. Breast cancer research and treatment 20050301
Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. Blood 20050201
Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: evidence for interactive effects of flavopiridol, LY 294002, roscovitine,wortmannin and UCN-01. Anticancer research 20050101
Inhibition of multiple pathways accounts for the antiapoptotic effects of flavopiridol on potassium withdrawal-induced apoptosis in neurons. Journal of molecular neuroscience : MN 20050101
New concepts in the treatment of acute myeloid malignancies: selected pathways for targeted therapy. Journal of biological regulators and homeostatic agents 20050101
Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 20050101
Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Anticancer research 20050101
Induction of apoptosis by flavopiridol in human neuroblastoma cells is enhanced under hypoxia and associated with N-myc proto-oncogene down-regulation. Clinical cancer research : an official journal of the American Association for Cancer Research 20041215
Cyclooxygenase-2 activity contributes to neuronal expression of cyclin D1 after anoxia/ischemia in vitro and in vivo. Brain research. Molecular brain research 20041206
Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell cycle (Georgetown, Tex.) 20041201
E2F4 deficiency promotes drug-induced apoptosis. Cancer biology & therapy 20041201
The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Molecular cancer therapeutics 20041201
Molecular models of cyclin-dependent kinase 1 complexed with inhibitors. Biochemical and biophysical research communications 20041112
Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia 20041101
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Molecular pharmacology 20041001
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Investigational new drugs 20040801
Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040801
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 20040801
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 20040715
Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse. International journal of radiation oncology, biology, physics 20040715
Transcriptional signature of flavopiridol-induced tumor cell death. Molecular cancer therapeutics 20040701
Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name? Molecular cancer therapeutics 20040701
Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clinical cancer research : an official journal of the American Association for Cancer Research 20040615
Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature. Lung cancer (Amsterdam, Netherlands) 20040601
Binding of the potential antitumour agent indirubin-5-sulphonate at the inhibitor site of rabbit muscle glycogen phosphorylase b. Comparison with ligand binding to pCDK2-cyclin A complex. European journal of biochemistry 20040601
Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anti-cancer drugs 20040601
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer research 20040515
Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer research 20040515
Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines. Oncology reports 20040501
Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20040501
Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. Molecular cancer therapeutics 20040401
Combining flavopiridol with various signal transduction inhibitors. Oncology reports 20040301
Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Molecular pharmacology 20040301
Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clinical cancer research : an official journal of the American Association for Cancer Research 20040301
Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. The Journal of biological chemistry 20040206
Inhibition of cell cycle pathway by flavopiridol promotes survival of cerebellar granule cells after an excitotoxic treatment. The Journal of pharmacology and experimental therapeutics 20040201
Flavopiridol: where do we stand in chronic lymphocytic leukemia? Leukemia 20040201
Flavopiridol inhibits the growth of GL261 gliomas in vivo: implications for malignant glioma therapy. Cell cycle (Georgetown, Tex.) 20040201
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 20040201
Coordination of transcription, RNA processing, and surveillance by P-TEFb kinase on heat shock genes. Molecular cell 20040116
A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics. Antiviral research 20040101
Cell-cycle targeted therapies. The Lancet. Oncology 20040101
Flavopiridol as a radio-sensitizer for esophageal cancer cell lines. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 20040101
Gemcitabine-induced apoptosis in a drug-resistant mouse leukemia L1210 cell line that does not express p53. Advances in enzyme regulation 20040101
In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time. Cancer chemotherapy and pharmacology 20031201
Flavopiridol downregulates the expression of both the inducible NO synthase and p27(kip1) in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia 20031201
The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 20031201
The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy. International journal of clinical pharmacology and therapeutics 20031201
The inducible NO synthase is downregulated during apoptosis of malignant cells from B-cell chronic lymphocytic leukemia induced by flavopiridol and polyphenols. Annals of the New York Academy of Sciences 20031201
Inhibition of CDKs: a strategy for preventing kainic acid-induced apoptosis in neurons. Annals of the New York Academy of Sciences 20031201
Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor. Molecular pharmacology 20031101
Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Cancer research 20031101
Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2). Life sciences 20031017
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 20031016
Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis. Neuropharmacology 20031001
Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. The Journal of pharmacology and experimental therapeutics 20031001
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. The Annals of pharmacotherapy 20031001
Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction. Clinical cancer research : an official journal of the American Association for Cancer Research 20031001
Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clinical cancer research : an official journal of the American Association for Cancer Research 20030815
Phase II study of flavopiridol in patients with advanced colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology 20030801
Cyclin-dependent kinase inhibitors. Current opinion in pharmacology 20030801
A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors. Journal of medicinal chemistry 20030717
Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer chemotherapy and pharmacology 20030701
Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer. Cancer research 20030701
Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer research 20030615
Commentary: effect of flavonoids on normal and leukemic cells. Leukemia research 20030601
Flavonoid effects on normal and leukemic cells. Leukemia research 20030601
The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines. Melanoma research 20030601
Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Molecular cancer therapeutics 20030601
Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030501
Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway. The Journal of thoracic and cardiovascular surgery 20030501
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer research 20030415
Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol. The Journal of antimicrobial chemotherapy 20030401
Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition. The Journal of neuroscience : the official journal of the Society for Neuroscience 20030215
Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer research 20030201
Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. Anti-cancer drugs 20030201
Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. Clinical cancer research : an official journal of the American Association for Cancer Research 20030201
Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Molecular cancer therapeutics 20030201
Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism. Leukemia & lymphoma 20030201
Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells. Oral oncology 20030101
Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer research 20030101
Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer research 20030101
Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Molecular cancer therapeutics 20030101
Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol. Molecular cancer therapeutics 20030101
Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research 20030101
Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies. Current medicinal chemistry. Anti-cancer agents 20030101
Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol. Cell cycle (Georgetown, Tex.) 20030101
Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor. Cell cycle (Georgetown, Tex.) 20030101
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers. Annals of oncology : official journal of the European Society for Medical Oncology 20030101
c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases. Cell cycle (Georgetown, Tex.) 20030101
Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer chemotherapy and pharmacology 20021201
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clinical cancer research : an official journal of the American Association for Cancer Research 20021101
Zebrafish: a preclinical model for drug screening. Assay and drug development technologies 20021101
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021001
Cyclin-dependent kinases as new targets for the prevention and treatment of cancer. Hematology/oncology clinics of North America 20021001
A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma. Biomedical chromatography : BMC 20020901
Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clinical cancer research : an official journal of the American Association for Cancer Research 20020901
Clinical trials referral resource. Flavopiridol. Oncology (Williston Park, N.Y.) 20020901
Hematologic malignancies: new developments and future treatments. Seminars in oncology 20020801
Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer research 20020715
Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 20020701
Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Molecular cancer therapeutics 20020701
Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. International journal of cancer 20020610
Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways. Molecular pharmacology 20020601
Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy. Seminars in oncology 20020601
Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. The Journal of pharmacology and experimental therapeutics 20020501
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. The Annals of pharmacotherapy 20020501
Evidence for CRK3 participation in the cell division cycle of Trypanosoma cruzi. Molecular and biochemical parasitology 20020501
In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharmaceutical research 20020501
Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochemical and biophysical research communications 20020426
Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. Journal of medicinal chemistry 20020425
Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer research 20020415
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020415
Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leukemia & lymphoma 20020401
Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer research 20020315
Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leukemia research 20020301
Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors. The Journal of biological chemistry 20020215
Inhibition of cyclin-dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the rat. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20020201
The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Molecular cancer therapeutics 20020201
The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. The oncologist 20020101
Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis. Cancer biology & therapy 20020101
[Report on 93rd AACR]. Bulletin du cancer 20020101
CDK inhibitors: cell cycle arrest versus apoptosis. Cell cycle (Georgetown, Tex.) 20020101
Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel. Cancer biology & therapy 20020101
Role reversal for anticancer agents. Cancer biology & therapy 20020101
Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes. Journal of the American Society of Nephrology : JASN 20011201
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research 20011201
Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. Molecular pharmacology 20011101
Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1. Neoplasia (New York, N.Y.) 20011101
Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. The Journal of biological chemistry 20010824
Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clinical cancer research : an official journal of the American Association for Cancer Research 20010801
Flavopiridol. National Cancer Institute. Current opinion in investigational drugs (London, England : 2000) 20010801
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell death and differentiation 20010701
Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. British journal of haematology 20010701
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 20010601
Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia 20010601
Mechanisms of action of flavopiridol. Critical reviews in oncology/hematology 20010501
Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases. Hepatology (Baltimore, Md.) 20010501
Effect of P-glycoprotein on flavopiridol sensitivity. British journal of cancer 20010501
The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana. Molecular and biochemical parasitology 20010406
In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9. Drug metabolism and disposition: the biological fate of chemicals 20010401
Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010401
[CDK inhibitors for therapy of cancer]. Nihon rinsho. Japanese journal of clinical medicine 20010401
Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer research 20010315
The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer research 20010315
Characterization of the Trypanosoma cruzi Cdc2p-related protein kinase 1 and identification of three novel associating cyclins. Molecular and biochemical parasitology 20010301
The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. Archives of biochemistry and biophysics 20010215
Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol. Clinical cancer research : an official journal of the American Association for Cancer Research 20010201
Strategies to circumvent SV40 oncoprotein expression in malignant pleural mesotheliomas. Seminars in cancer biology 20010201
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? The Journal of biological chemistry 20010105
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 20010101
Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 20010101
Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes. Blood cells, molecules & diseases 20010101
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome biology 20010101
Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release. The Journal of biological chemistry 20001013
Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. International journal of oncology 20001001
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 20000715
Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clinical cancer research : an official journal of the American Association for Cancer Research 19991001
Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat. Circulation 19990810
Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 19990701
Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer research 19990601
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 19981115
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. The Journal of clinical investigation 19981101
Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 19981101
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (New York, N.Y.) 19980724
Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood 19980401
Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 19980115
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer research 19960701
Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochemical and biophysical research communications 19940615
Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochemical pharmacology 19931117
Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. Journal of the National Cancer Institute 19921118

Related Products

© 2019 Angene International Limited. All rights Reserved.